Selective serotonin reuptake inhibitors (SSRIs) and vascular endothelial growth factor (VEGF) inhibitors were strongly represented in our final network, aligning gene targets of the pathophysiological processes angiogenesis and inflammation, both of which are highly relevant for complications of PD treatment. This evidence concerns the gene VEGFA and Parkinson disease.